Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United State...
| Metric Name | Value | Trend | |
|---|---|---|---|
| Dividend Yield | 0.0% | ||
| P/E Ratio | 49.0x | ||
| Revenue | 277.2 M | ||
| Net Income to Company | 27.309 M |
| (presentment in millions) | Trailing Twelve Months | Fiscal Quarters | |||
|---|---|---|---|---|---|
| Period Ending | Dec-22 | Dec-23 | Dec-24 | Dec-23 | Dec-24 |
| Income Statement | |||||
| Revenue | 723 | 232 | 277 | 56 | 72 |
| Operating Income | 290 | (30) | 0.89 | (6.50) | 0.57 |
| Net Profit | 293 | (6.39) | 27 | 0.22 | 7.05 |
| Diluted EPS | 1.97 | -0.050 | 0.20 | -0.000081 | 0.043 |
| EBITDA | 294 | (26) | 5.52 | (5.38) | 1.76 |
| Balance Sheet | |||||
| Cash & ST Invest. | 624 | 742 | 714 | 742 | 714 |
| Current Assets | 917 | 859 | 849 | 859 | 849 |
| Total Assets | 986 | 997 | 986 | 997 | 986 |
| Current Liabilities | 150 | 62 | 79 | 62 | 79 |
| Total Liabilities | 405 | 375 | 389 | 375 | 389 |
| Total Equity | 581 | 622 | 597 | 622 | 597 |
| Total Debt | 258 | 257 | 254 | 257 | 254 |
| Cash Flow Statement | |||||
| Cash Flow Operations | 63 | 101 | 67 | 14 | 53 |
| Cash From Investing | (316) | (154) | (18) | (20) | 23 |
| Cash From Financing | 20 | 1.39 | (102) | 1.78 | (99) |
| Free Cash Flow | 56 | 96 | 60 | 12 | 50 |